Biovian announces over €50 million investment in manufacturing facility in Turku, Finland
News and updates
Author: Gareth Davies
3P Biopharmaceuticals lands in the United States.
3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.
The Regional Minister for Economic and Business Development Mikel Irujo meets with the management of 3P Biopharmaceuticals and its majority shareholder Keensight Capital.
3PBIOVIAN’s in-house Solution preparation team prepares and provides a wide variety of solutions
3P Biopharmaceuticals is moving forward with its expansion plan and the adaptation of its facilities.
3P Biopharmaceuticals increases its microbial production capacity with the installation of a 500 L fermenter.
3P Biopharmaceuticals among the 500 fastest growing companies in Spain
3P Biopharmaceuticals brings together leading international experts in biomedicine to celebrate its 15th anniversary.
Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2
BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1
3P Biopharmaceuticals among the 100 best companies to work for in Spain
Biovian Announces the Appointment of a New Board Member − Dr. Uwe Gottschalk
3P Biopharmaceuticals celebrates its 15th anniversary with Juan Carlos Unzué.
3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.
3P Biopharmaceuticals awards prize for the best Final Degree Project in Pharmacy at the University of Navarra